Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion-mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study.
Girard N, Park K, Lee SH, Viteri S, Schioppa CA, Diels J, Oguz M, Rodrigues BH, Rahhali N, Sermon J, Ghilotti F, Li T, Thayu M, Knoblauch RE, Mahadevia P, Cho BC. Girard N, et al. Among authors: sermon j. Cancer Treat Res Commun. 2024;40:100832. doi: 10.1016/j.ctarc.2024.100832. Epub 2024 Jul 9. Cancer Treat Res Commun. 2024. PMID: 39033692 Free article. Clinical Trial.
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.
Chouaid C, Bosquet L, Girard N, Kron A, Scheffler M, Griesinger F, Sebastian M, Trigo J, Viteri S, Knott C, Rodrigues B, Rahhali N, Cabrieto J, Diels J, Perualila NJ, Schioppa CA, Sermon J, Toueg R, Erdmann N, Mielke J, Nematian-Samani M, Martin-Fernandez C, Pfaira I, Li T, Mahadevia P, Wolf J. Chouaid C, et al. Among authors: sermon j. Adv Ther. 2023 Mar;40(3):1187-1203. doi: 10.1007/s12325-022-02408-7. Epub 2023 Jan 18. Adv Ther. 2023. PMID: 36652175 Free PMC article.
Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated EGFR Exon 20 insertion-mutated non-small-cell lung cancer.
Kim TM, Girard N, Leighl NB, Sabari J, Rahhali N, Schioppa CA, Diels J, Sermon J, Chandler C, Kapetanakis V, Jain R, Li T, Sanden SV. Kim TM, et al. Among authors: sermon j. Future Oncol. 2024 Mar;20(8):447-458. doi: 10.2217/fon-2023-0620. Epub 2023 Oct 26. Future Oncol. 2024. PMID: 37882460 Free article.
Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations.
Christopoulos P, Girard N, Proto C, Soares M, Lopez PG, van der Wekken AJ, Popat S, Diels J, Schioppa CA, Sermon J, Rahhali N, Pick-Lauer C, Adamczyk A, Penton J, Wislez M. Christopoulos P, et al. Among authors: sermon j. Cancers (Basel). 2023 Nov 8;15(22):5326. doi: 10.3390/cancers15225326. Cancers (Basel). 2023. PMID: 38001589 Free PMC article.
Patient-reported outcomes in non-small cell lung cancer: psychometric evaluation of the PROMIS PF-SF 8c and NSCLC-SAQ in two phase 3 clinical trials.
Houts CR, Savord A, Gardner MJ, Mattera M, Peipert JD, Agrawal T, Baig M, Barala P, Bauml J, Diorio B, Girvin A, Sermon J, Shah S, Withelder M, Wortman-Vayn H, Schuchard J. Houts CR, et al. Among authors: sermon j. Qual Life Res. 2024 Dec 5. doi: 10.1007/s11136-024-03846-2. Online ahead of print. Qual Life Res. 2024. PMID: 39636512
1:2 entrainment is not a device-induced artefact, except when it is.
Sermon JJ, Benjaber M, Duchet B, Anso J, Olaru M, Starr PA, Denison T. Sermon JJ, et al. Brain Stimul. 2024 Mar-Apr;17(2):149-151. doi: 10.1016/j.brs.2024.01.010. Epub 2024 Feb 6. Brain Stimul. 2024. PMID: 38331023 Free PMC article. No abstract available.
35 results